Christoph Straube1, Greeshma Elpula2, Jens Gempt3, Julia Gerhardt3, Stefanie Bette4, Claus Zimmer4, Friederike Schmidt-Graf5, Bernhard Meyer3, Stephanie E Combs2,6. 1. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Ismaninger Straße 22, 81675, München, Germany. Christoph.Straube@mri.tum.de. 2. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Ismaninger Straße 22, 81675, München, Germany. 3. Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München (TUM), München, Germany. 4. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München (TUM), München, Germany. 5. Department of Neurology, Klinikum rechts der Isar, Technische Universität München (TUM), München, Germany. 6. Institute for Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Oberschleißheim, Germany.
Abstract
BACKGROUND: Currently, patients with gross total resection (GTR) of recurrent glioblastoma (rGBM) undergo adjuvant chemotherapy or are followed up until progression. Re-irradiation, as one of the most effective treatments in macroscopic rGBM, is withheld in this situation, as uncertainties about the pattern of re-recurrence, the target volume, and also the efficacy of early re-irradiation after GTR exist. METHODS: Imaging and clinical data from 26 consecutive patients with GTR of rGBM were analyzed. The spatial pattern of recurrences was analyzed according to the RANO-HGG criteria ("response assessment in neuro-oncology criteria for high-grade gliomas"). Progression-free (PFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. Furthermore, a systematic review was performed in PubMed. RESULTS: All but 4 patients underwent adjuvant chemotherapy after GTR. Progression was diagnosed in 20 of 26 patients and 70% of recurrent tumors occurred adjacent to the resection cavity. The median extension beyond the edge of the resection cavity was 20 mm. Median PFS was 6 months; OS was 12.8 months. We propose a target volume containing the resection cavity and every contrast enhancing lesion as the gross tumor volume (GTV), a spherical margin of 5-10 mm to generate the clinical target volume (CTV), and a margin of 1-3 mm to generate the planning target volume (PTV). Re-irradiation of this volume is deemed to be safe and likely to prolong PFS. CONCLUSION: Re-irradiation is worth considering also after GTR, as the volumes that need to be treated are limited and re-irradiation has already proven to be a safe treatment option in general. The strategy of early re-irradiation is currently being tested within the GlioCave/NOA 17/Aro 2016/03 trial.
BACKGROUND: Currently, patients with gross total resection (GTR) of recurrent glioblastoma (rGBM) undergo adjuvant chemotherapy or are followed up until progression. Re-irradiation, as one of the most effective treatments in macroscopic rGBM, is withheld in this situation, as uncertainties about the pattern of re-recurrence, the target volume, and also the efficacy of early re-irradiation after GTR exist. METHODS: Imaging and clinical data from 26 consecutive patients with GTR of rGBM were analyzed. The spatial pattern of recurrences was analyzed according to the RANO-HGG criteria ("response assessment in neuro-oncology criteria for high-grade gliomas"). Progression-free (PFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. Furthermore, a systematic review was performed in PubMed. RESULTS: All but 4 patients underwent adjuvant chemotherapy after GTR. Progression was diagnosed in 20 of 26 patients and 70% of recurrent tumors occurred adjacent to the resection cavity. The median extension beyond the edge of the resection cavity was 20 mm. Median PFS was 6 months; OS was 12.8 months. We propose a target volume containing the resection cavity and every contrast enhancing lesion as the gross tumor volume (GTV), a spherical margin of 5-10 mm to generate the clinical target volume (CTV), and a margin of 1-3 mm to generate the planning target volume (PTV). Re-irradiation of this volume is deemed to be safe and likely to prolong PFS. CONCLUSION: Re-irradiation is worth considering also after GTR, as the volumes that need to be treated are limited and re-irradiation has already proven to be a safe treatment option in general. The strategy of early re-irradiation is currently being tested within the GlioCave/NOA 17/Aro 2016/03 trial.
Entities:
Keywords:
Glioblastoma; Pattern of recurrence; Recurrence; Survival; Target volume
Authors: Robert E Elliott; Erik C Parker; Stephen C Rush; Stephen P Kalhorn; Yaron A Moshel; Ashwatha Narayana; Bernadine Donahue; John G Golfinos Journal: World Neurosurg Date: 2011 Jul-Aug Impact factor: 2.104
Authors: F S Lautenschlaeger; R Dumke; M Schymalla; H Hauswald; B Carl; M Stein; U Keber; A Jensen; R Engenhart-Cabillic; F Eberle Journal: Strahlenther Onkol Date: 2021-09-14 Impact factor: 4.033
Authors: Asgeir S Jakola; David Bouget; Ingerid Reinertsen; Anne J Skjulsvik; Lisa Millgård Sagberg; Hans Kristian Bø; Sasha Gulati; Kristin Sjåvik; Ole Solheim Journal: J Neurooncol Date: 2020-01-09 Impact factor: 4.130
Authors: Barbara Witulla; Nicole Goerig; Florian Putz; Benjamin Frey; Tobias Engelhorn; Arnd Dörfler; Michael Uder; Rainer Fietkau; Christoph Bert; Frederik Bernd Laun Journal: PLoS One Date: 2020-01-06 Impact factor: 3.240